The mutant isocitrate dehydrogenase 1 product, 2‑hydroxyglutarate, activates MutT homolog 1 in glioma cells via the augmentation of reactive oxygen species levels

Bhavya,Bharathan; Anand,Chellapan Reghuvaran; Urulangodi,Madhusoodanan; Sreelakshmi,Kalapurakkal; Deepti,Akkihebbal Narasimhaiah; Menon,Girish Ramachandran; Kesavapisharady,Krishnakumar; Easwer,Hariharan Venkat; Gopala,Srinivas

doi:10.3892/wasj.2022.174

The mutant isocitrate dehydrogenase 1 product, 2‑hydroxyglutarate, activates MutT homolog 1 in glioma cells via the augmentation of reactive oxygen species levels

Authors:
- Bharathan Bhavya
- Chellapan Reghuvaran Anand
- Madhusoodanan Urulangodi
- Kalapurakkal Sreelakshmi
- Akkihebbal Narasimhaiah Deepti
- Girish Ramachandran Menon
- Krishnakumar Kesavapisharady
- Hariharan Venkat Easwer
- Srinivas Gopala
View Affiliations

Affiliations: Department of Biochemistry, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala 695011, India, Department of Pathology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala 695011, India, Department of Neurosurgery, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala 695011, India
Published online on: October 3, 2022 https://doi.org/10.3892/wasj.2022.174
Article Number: 39
Copyright: © Bhavya et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MutT homolog1 (MTH1) is an enzyme responsible for removing oxidized nucleotides from cells. The activation of MTH1 has been reported in a number of cancer cell types and is considered to be responsible for imparting resistance towards anticancer drugs. While there are several known mechanisms for the activation of MTH1 in cancer cells, the present study aimed to evaluate the role of mutant isocitrate dehydrogenase1 (mIDH1)‑mediated reactive oxygen species (ROS) production in the activation of MTH1 in glioma cells. MTH1 was found to be upregulated in both mIDH1‑expressing cells and 2-hydroxyglutarate (2‑HG)‑treated cells. mIDH1 and its product, 2‑HG, increased the levels of ROS in cultured glioblastoma cells. Furthermore, the increased expression and activity of MTH1 were observed in glioma tissues harboring mIDH1 compared to tissues with wild‑type IDH1. On the whole, the findings of the present study unveil a novel mechanism of activation of MTH1 in glioma cells harboring mutant IDH1.

View Figures

View References

1	Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR and Yang C: IDH mutation in glioma: Molecular mechanisms and potential therapeutic targets. Br J Cancer. 122:1580–1589. 2020.PubMed/NCBI View Article : Google Scholar
2	Shi J, Zuo H, Ni L, Xia L, Zhao L, Gong M, Nie D, Gong P, Cui D, Shi W and Chen J: An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation. Neurol Sci. 35:839–845. 2014.PubMed/NCBI View Article : Google Scholar
3	Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008.PubMed/NCBI View Article : Google Scholar
4	Komori T: The 2021 WHO classification of tumors, 5th edition, central nervous system tumors: The 10 basic principles. Brain Tumor Pathol. 39:47–50. 2022.PubMed/NCBI View Article : Google Scholar
5	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
6	Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap J, Henneman P, Khurshed M, Lenting K, Mul AN, et al: Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198. Cancer Res. 75:4790–4802. 2015.PubMed/NCBI View Article : Google Scholar
7	Qing X, Shao Z, Lv X, Pu F, Gao F, Liu L and Shi D: Anticancer effect of (S)-crizotinib on osteosarcoma cells by targeting MTH1 and activating reactive oxygen species. Anticancer Drugs. 29:341–352. 2018.PubMed/NCBI View Article : Google Scholar
8	Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Ström CE, Svensson LM, Schultz N, Lundbäck T, Einarsdottir BO, et al: MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 508:215–221. 2014.PubMed/NCBI View Article : Google Scholar
9	Bhavya B, Easwer HV, Vilanilam GC, Anand CR, Sreelakshmi K, Urulangodi M, Rajalakshmi P, Neena I, Padmakrishnan CJ, Menon GR, et al: MutT homolog1 has multifaceted role in glioma and is under the apparent orchestration by hypoxia inducible factor1 alpha. Life Sci. 264(118673)2020.PubMed/NCBI View Article : Google Scholar
10	Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, et al: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 324:261–265. 2009.PubMed/NCBI View Article : Google Scholar
11	Gilbert MR, Liu Y, Neltner J, Pu H, Morris A, Sunkara M, Pittman T, Kyprianou N and Horbinski C: Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol. 127:221–233. 2014.PubMed/NCBI View Article : Google Scholar
12	Chen L, Li X, Liu L, Yu B, Xue Y and Liu Y: Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function. Oncol Rep. 33:1465–1474. 2015.PubMed/NCBI View Article : Google Scholar
13	Behrend L, Henderson G and Zwacka RM: Reactive oxygen species in oncogenic transformation. Biochem Soc Trans. 31:1441–1444. 2003.PubMed/NCBI View Article : Google Scholar
14	Reczek CR and Chandel NS: The two faces of reactive oxygen species in cancer. Annu Rev Cancer Biol. 1:79–98. 2017.
15	Mohamed Yusoff AA, Zulfakhar FN, Sul'ain MD, Idris Z and Abdullah JM: Association of the IDH1 C.395G>A (R132H) mutation with histological type in malay brain tumors. Asian Pac J Cancer Prev. 17:5195–5201. 2016.PubMed/NCBI View Article : Google Scholar
16	Bhavya B, Anand CR, Madhusoodanan UK, Rajalakshmi P, Krishnakumar K, Easwer HV, Deepti AN and Gopala S: To be wild or mutant: Role of isocitrate dehydrogenase 1 (IDH1) and 2-hydroxy glutarate (2-HG) in gliomagenesis and treatment outcome in glioma. Cell Mol Neurobiol. 40:53–63. 2020.PubMed/NCBI View Article : Google Scholar
17	Shi J, Sun B, Shi W, Zuo H, Cui D, Ni L and Chen J: Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. Tumour Biol. 36:655–662. 2015.PubMed/NCBI View Article : Google Scholar
18	Reiter-Brennan C, Semmler L and Klein A: The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas. Contemp Oncol (Pozn). 22:215–222. 2018.PubMed/NCBI View Article : Google Scholar